| Histology (ICD-O) (2) | All Races | Asian/Other | Black | Hispanic | White | ||||||
| < 50 | 50 + | < 50 | 50 + | < 50 | 50 + | < 50 | 50 + | < 50 | 50 + | ||
| Breast-Invasive | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | |
| Infiltrating duct carcinoma, NOS (8500) | 72.5 | 71.4 | 74.1 | 73.1 | 71.0 | 68.5 | 70.5 | 71.1 | 72.9 | 71.5 | |
| Lobular carcinoma (8520,8521) | 5.1 | 7.9 | 3.2 | 4.2 | 3.6 | 5.4 | 3.8 | 5.9 | 5.8 | 8.4 | |
| Infiltrating duct and lobular carcinoma (8522) | 4.2 | 4.5 | 3.8 | 3.3 | 2.8 | 3.2 | 3.3 | 4.2 | 4.7 | 4.7 | |
| Comedocarcinoma (8501) | 4.1 | 2.3 | 5.3 | 4.2 | 5.1 | 2.8 | 4.2 | 2.7 | 3.8 | 2.2 | |
| Adenocarcinoma, NOS (8140) | 2.4 | 2.7 | 2.1 | 2.6 | 3.2 | 4.2 | 3.1 | 2.9 | 2.2 | 2.5 | |
| Mucinous & mucin-producing adenocarcinoma (8480,8481) | 1.2 | 2.8 | 3.1 | 3.3 | 0.8 | 3.4 | 1.2 | 2.9 | 1.0 | 2.7 | |
| Unspecified carcinoma or cancer, NOS | 1.8 | 1.9 | 1.4 | 2.2 | 2.1 | 3.0 | 2.8 | 2.3 | 1.5 | 1.8 | |
| Medullary carcinoma (8510,8512) | 3.2 | 1.2 | 2.4 | 1.8 | 5.5 | 2.4 | 4.9 | 2.0 | 2.7 | 1.1 | |
| Inflammatory carcinoma (8530) | 2.0 | 1.2 | 1.5 | 1.5 | 2.8 | 2.1 | 3.0 | 1.9 | 1.8 | 1.0 | |
| Tubular adenocarcinoma (8211) | 0.9 | 1.3 | 0.3 | 0.6 | 0.4 | 0.7 | 0.5 | 1.0 | 1.1 | 1.4 | |
| Paget's disease (8540-8543) | 1.1 | 0.9 | 0.8 | 1.0 | 1.4 | 1.4 | 0.9 | 0.9 | 1.1 | 0.9 | |
| Papillary adenocarcinoma (8050,8260,8503) | 0.4 | 0.7 | 0.8 | 1.2 | 0.4 | 1.6 | 0.4 | 0.9 | 0.4 | 0.6 | |
| Sarcoma | 0.5 | 0.2 | 0.8 | 0.2 | 0.1 | 0.1 | 0.8 | 0.4 | 0.4 | 0.2 | |
| Scirrhous adenocarcinoma (8141) | 0.1 | 0.2 | 0.2 | 0.1 | 0.1 | 0.4 | 0.2 | 0.4 | 0.1 | 0.2 | |
| All other neoplasms | 0.4 | 0.8 | 0.4 | 0.9 | 0.8 | 0.9 | 0.4 | 0.6 | 0.4 | 0.8 | |
| Breast-in situ | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | |
| Non-infiltrating intraductal carcinoma, NOS (8500) | 51.2 | 56.8 | 50.4 | 58.2 | 55.7 | 60.7 | 52.7 | 55.3 | 51.1 | 56.7 | |
| Non-infiltrating comedocarcinoma (8501) | 17.9 | 18.0 | 24.8 | 16.8 | 16.2 | 11.8 | 15.9 | 17.1 | 17.6 | 18.6 | |
| Lobular carcinoma in situ (8520,8521) | 19.1 | 11.6 | 9.8 | 4.6 | 16.2 | 8.7 | 18.5 | 11.4 | 20.0 | 11.9 | |
| Papillary adenocarcinoma in situ (8050,8260,8503) | 3.8 | 6.1 | 6.3 | 11.6 | 4.8 | 9.8 | 3.8 | 8.2 | 3.4 | 5.5 | |
| Intraductal and lobular carcinoma in situ (8522) | 4.3 | 3.5 | 3.5 | 1.5 | 4.8 | 6.6 | 5.3 | 4.6 | 4.2 | 3.6 | |
| All other in situ neoplasms | 3.7 | 4.0 | 5.1 | 7.3 | 2.4 | 2.5 | 3.8 | 3.4 | 3.6 | 3.8 | |
Source: California Cancer Registry, November 1994. Excludes lymphohematopoietic neoplasms of the breast (ICD-O, Field Trial edition, histology codes 9590-9970) (2).
1 Race/ethnicity categories are mutually exclusive. Persons of Hispanic ethnicity are identified by medical record and/or surname, and may be of any race. Persons of unknown race/ethnicity are excluded from race-specific data.
2 Numbers in parentheses are ICD-O, Field Trial edition, histology codes (2). Where not specified, groups are as defined by Berg (11). NOS=not otherwise specified.
Return to Table of Contents
Return to Chapter 5
Return to Table 5.9
Go to Table 5.11